ELEVAI Labs Inc
NASDAQ:ELAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Holmen AB
STO:HOLM B
|
SE |
ELEVAI Labs Inc
Total Current Liabilities
ELEVAI Labs Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
ELEVAI Labs Inc
NASDAQ:ELAB
|
Total Current Liabilities
$1.8m
|
CAGR 3-Years
219%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kenvue Inc
NYSE:KVUE
|
Total Current Liabilities
$5.9B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Safety Shot Inc
NASDAQ:SHOT
|
Total Current Liabilities
$9.4m
|
CAGR 3-Years
82%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
|
Horizon Kinetics Holding Corp
OTC:HKHC
|
Total Current Liabilities
$49m
|
CAGR 3-Years
119%
|
CAGR 5-Years
82%
|
CAGR 10-Years
44%
|
|
|
Bonk Inc
NASDAQ:BNKK
|
Total Current Liabilities
$9.4m
|
CAGR 3-Years
82%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
|
F
|
Functional Brands Inc
NASDAQ:MEHA
|
Total Current Liabilities
$5.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ELEVAI Labs Inc
Glance View
ELEVAI Labs Inc is a US-based company operating in Personal Care Products industry. The company is headquartered in Newport Beach, California. The company went IPO on 2023-11-21. Elevai Labs, Inc. is a physician-dispensed skincare company. The firm conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. The company produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare products. The company has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.
See Also
What is ELEVAI Labs Inc's Total Current Liabilities?
Total Current Liabilities
1.3m
USD
Based on the financial report for Dec 31, 2023, ELEVAI Labs Inc's Total Current Liabilities amounts to 1.3m USD.
What is ELEVAI Labs Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
219%
Over the last year, the Total Current Liabilities growth was 120%. The average annual Total Current Liabilities growth rates for ELEVAI Labs Inc have been 219% over the past three years .
